About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to ...
The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...
A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...
The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...
Official data shows that since 2019, this medication has been linked to 23 deaths and 1,179 serious adverse reactions in the ...
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...
The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027 ...
Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...
3d
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback